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Some of the most interesting questions in biology
today, in my view, derive from the real advances in
neuropsychiatry that have come largely from human
genetics. Research in autism spectrum disorders
(ASDs) has been leading the way, mainly because it
has become especially well funded and has recently
attracted many outstanding scientists. (I must make it
clear that I am an outsider in this field, as I have never
worked on any neuropsychiatric disorder).Reversibility in monogenetic animal models
Autism spectrum disorder genetics
More than 25 mutations that have a large effect on risk
have now been strongly implicated in ASDs. Some are
inherited, whereas others are de novo [1-5]. All of them
are rare: no one of the affected genes appears to be in-
volved in more than 1% of ASDs. Interestingly, so far,
none of them has been found to be specific for ASDs, in
that most have also been implicated in other neuro-
psychiatric disorders, including, for example, intellectual
disability, schizophrenia and epilepsy. Even in the same
family, the same large-effect mutations can contribute to
different neuropsychiatric disorders. There thus seems
to be a deep genetic connection between these disorders
that is not understood. One possibility is that they all re-
flect synaptic dysfunction: there is increasing evidence,
for example, that mutations that affect genes that encode
proteins that work only or primarily at synapses can
greatly increase the risk of ASDs and of other neuro-
psychiatric disorders [5].
From analyses of copy number variants (CNVs) and
exome sequencing, it is now estimated that mutations in
hundreds of genes can substantially increase the risk of
developing ASD, the predisposing mutant genes varying
from one individual to another [1-5]. Thus, ASDs areCorrespondence: m.raff@ucl.ac.uk
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unless otherwise stated.genetically heterogeneous, and their well known clinical
heterogeneity is presumably at least in part a reflection
of this genetic heterogeneity. There is also evidence that
more than one rare, large-effect mutation can contribute
to ASD in a single individual. So although ASDs are
common (approximately 1% prevalence), the genetic
underpinning in each individual is rare, and may even be
unique, much as an individual cancer is genetically
unique. All of this is remarkable progress, given that,
until recently, very little was known about ASD genetics.Once a large-effect mutation is identified as a risk factor
for a neuropsychiatric disorder, one can make a genetic
animal model of it, in which the underlying neuro-
biological basis of the disorder can be studied. Such ap-
proaches have already yielded important insights into
the nature of ASDs. The studies on mouse models of the
monogenetic, or syndromic, forms of these disorders -
such as Rett and fragile X syndromes - have been par-
ticularly informative. These single-gene conditions are
neurologically complex, and the core features of autism
occur in about half of the affected individuals. The most
dramatic and surprising finding has been that both con-
ditions can be largely reversed in adult mice carrying the
mutations: if the brain problem is corrected either gene-
tically (in Rett, where the mutation is in MeCP2) [6] or
with drugs that correct an abnormal downstream signal-
ing pathway (in fragile X, where the mutant gene is
FMR1) [7], most of the behavioral and physiological ab-
normalities go away. This was totally unexpected, as
these are developmental brain disorders: but these re-
markable results demonstrate that the serious neuro-
logical defects seen in these mutant mice reflect
reversible functional defects in the adult brain. This is
potentially very good news for the future of drug thera-
pies for humans with ASDs (and probably for some
other neuropsychiatric disorders as well), although it is
still uncertain whether ASDs in humans are similarly
reversible in adults.is an Open Access article distributed under the terms of the Creative Commons
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synaptic dysfunction, however, reversibility should not
be so surprising: synaptic plasticity is, after all, presu-
mably the basis for all of normal brain function that de-
pends on memory, and it persists well into adulthood,
which is why even as we age we can still learn and re-
member - at least some things. Moreover, some human
neuropsychiatric disorders spontaneously show dra-
matic, if temporary, reversibility. Bipolar disorder is the
clearest example: in this condition, individuals can
switch from extreme mania to deep depression and then
to apparent normality, and can do this repeatedly. It is
clear that the problem in bipolar disorder is an abnor-
mality in mood control, but we don’t know much about
the normal mood control system, let alone how it goes
wrong in bipolar disorder. The identification of large-
effect mutations that greatly increase the risk of this dis-
order, however, could lead to useful animal models,
which might then shed light on both the underlying
brain abnormality in bipolar individuals and the normal
mood control system.
If there is a synaptic problem in ASDs, what is it?
If synaptic dysfunction is at the heart of ASDs, what
exactly is the synaptic problem? Given the clinical and
genetic heterogeneity of ASDs, there is unlikely to be
one answer. There is evidence that there are defects in
the ratio of excitatory to inhibitory synaptic transmission
in some mouse ASD models, but it seems that the ratio
can be abnormally increased or decreased, and the ab-
normality can vary from one brain region to another,
even in the same mouse model [8].
Even if a consistent synaptic defect were found, it
would be a major challenge to relate it to a particular
behavioral phenotype. And how would you know
whether the defect is a primary result of the genetic de-
fect or a secondary effect of the brain’s attempt to com-
pensate? After all, the nervous system is a specialist in
compensatory adjustments.
Are abnormal genes the whole story?
Although genetic abnormalities are likely to play an im-
portant part in most ASDs, they are unlikely to be the
only contributor. If one identical twin develops an ASD,
there is a 70 to 90% chance that the other will too - but
it’s not 100%. Why not? The answer isn’t known, but the
acquisition of somatic mutations in the developing brain
could, in principle, be part of the answer.
Could environmental influences play a part? Although
there is no compelling evidence that adverse postnatal
environmental factors contribute to the risk of ASDs,
there is strong evidence that stressful conditions in utero
can do so: maternal infection early in pregnancy, for ex-
ample, can greatly increase the risk of ASDs (andschizophrenia) [9]. It remains a mystery how such
stresses in utero interact with predisposition genes in the
fetus.
Why the ASD ‘core’?
ASD individuals have two defining characteristics: im-
paired social communication and interactions; and re-
stricted and obsessive interests and behaviors. Together,
these constitute the autistic ‘core’. In addition, most in-
dividuals on the autistic spectrum have a number of
other neurological and psychiatric problems, which can
include intellectual disability, language impairment, sen-
sory and motor abnormalities, and so on.
A central mystery in ASDs is why mutations in so
many genes result in the core features of ASD. It is not
obvious why these features should occur together. What
connects them? There are various possible explanations.
One possibility is that the primary problem is the strong
drive for sameness and predictability (which is an im-
portant part of the restricted interests and obsessive be-
haviors phenotype), and this leads to a secondary social
withdrawal; after all, people are the least predictable ob-
jects in a developing child’s environment. Another possi-
bility is that the primary problem is an electrically 'noisy'
brain, which leads to a secondary social withdrawal and re-
stricted interests - to keep the noise level to a minimum.
Although many mysteries remain, considering the little
that was known up to a decade or so ago, there has been
staggering recent progress, which is bringing the neuro-
biology of ASDs and neuropsychiatric disorders out of
the darkness into the light. Much of what has been
learned so far is encouraging, and, as more high-risk
genes are discovered, progress can only accelerate.
Published: 5 June 2014
References
1. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L,
Thiruvahindrapuram B, Xu X, Ziman R, Wang Z, Vorstman JA, Thompson A,
Regan R, Pilorge M, Pellecchia G, Pagnamenta AT, Oliveira B, Marshall CR,
Magalhaes TR, Lowe JK, Howe JL, Griswold AJ, Gilbert J, Duketis E,
Dombroski BA, De Jonge MV, Cuccaro M, Crawford EL, Correia CT, Conroy J
et al (2014) Convergence of genes and cellular pathways dysregulated in
autism spectrum disorders. Am J Hum Gene 94:677–694
2. Ronemus M, Iossifov I, Levy D, Wigler M (2014) The role of de novo
mutations in the genetics of autism spectrum disorders. Nat Rev Genet
15:133–141
3. Krumm N, O’Roak BJ, Shendure J, Eichler EE (2014) A de novo convergence
of autism genetics and molecular neuroscience. Trends Neurosci 37:95–105
4. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B,
Schmitz-Abe K, Harmin DA, Adli M, Malik AN, D'Gama AM, Lim ET, Sanders SJ,
Mochida GH, Partlow JN, Sunu CM, Felie JM, Rodriguez J, Nasir RH, Ware J,
Joseph RM, Hill RS, Kwan BY, Al-Saffar M, Mukaddes NM, Hashmi A, Balkhy S,
Gascon GG, Hisama FM, LeClair E et al (2013) Using whole-exome sequencing
to identify inherited causes of autism. Neuron 77:259–273
5. Guillaume H, Ey E, Bourgeron T (2013) The genetic landscapes of autism
spectrum disorders. Annu Rev Genomics Hum Genet 14:191–213
6. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological
defects in a mouse model of Rett syndrome. Science 315:1143–1147
Raff BMC Biology 2014, 12:45 Page 3 of 3
http://www.biomedcentral.com/1741-7007/12/457. Michalon AI, Siderov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG,
Jaeschke G, Bear MF, Lindemann L (2012) Chronic pharmacological mGlu5
inhibition corrects fragile X in adult mice. Neuron 74:49–56
8. Etherton M, Földy C, Sharma M, Tabuchi K, Liu X, Shamloo M, Malenka RC,
Südhof TC (2011) Autism-linked neuroligin-3 R451C mutation differentially
alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A
108:13764–13769
9. Patterson PH (2011) Maternal infection and immune involvement in autism.
Trends Mol Med 17:389–394
doi:10.1186/1741-7007-12-45
Cite this article as: Raff M: Open questions: What has genetics told us
about autism spectrum disorders? BMC Biology 2014 12:45.
